Investor Relations SEClose
Contact Ortoma

Ortoma presenterar idag på Redeye Investor AW – Göteborg

Publicerat 15 Dec, 2022

 

Ortoma AB (publ) ("Ortoma" eller "Bolaget") presenterar idag den 15 december på Redeye Investor AW i Göteborg, presentationen hålls klockan 19.25. Ortomas VD Linus Byström kommer att presentera Bolaget.

 

VD Linus Byström presenterar Ortoma och ger en uppdatering kring bolagets verksamhet och utveckling på det livesända eventet Redeye Investor AW i Göteborg den 15 december klockan 19.25. Livesändningen av eventet kan ses på Redeyes hemsida: https://www.redeye.se/events/850217/investor-aw-goteborg-5

Ortoma – Improved Performance

 

För ytterligare information vänligen kontakta:

Ortomas vd Linus Byström
e-post: [email protected]

 

About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Spotlight Stock Market.